Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 760,113
  • Shares Outstanding, K 78,443
  • Annual Sales, $ 0 K
  • Annual Income, $ -247,300 K
  • EBIT $ -320 M
  • EBITDA $ -326 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.86

Options Overview Details

View History
  • Implied Volatility 233.04% (+88.11%)
  • Historical Volatility 41.12%
  • IV Percentile 86%
  • IV Rank 23.30%
  • IV High 792.98% on 07/28/25
  • IV Low 62.91% on 02/26/25
  • Expected Move (DTE 6) 0.70 (7.05%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 2,849
  • Volume Avg (30-Day) 1,552
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 76,883
  • Open Int (30-Day) 84,344
  • Expected Range 9.18 to 10.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.85
  • Number of Estimates 5
  • High Estimate -0.74
  • Low Estimate -0.93
  • Prior Year -0.79
  • Growth Rate Est. (year over year) -7.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.75 +12.91%
on 11/20/25
11.26 -12.26%
on 12/02/25
+0.89 (+9.90%)
since 11/19/25
3-Month
3.12 +216.67%
on 09/22/25
11.26 -12.26%
on 12/02/25
+6.66 (+206.36%)
since 09/19/25
52-Week
2.68 +268.66%
on 07/22/25
14.80 -33.22%
on 02/21/25
-2.13 (-17.74%)
since 12/19/24

Most Recent Stories

More News
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
The Best AI for Picking Stocks, Ranked by Performance

AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.

SOUN : 11.02 (+1.19%)
SMCI : 31.11 (+5.92%)
HUT : 44.12 (+14.33%)
MLTX : 13.39 (+0.98%)
LRMR : 3.65 (+6.41%)
REPL : 9.88 (+1.96%)
ASTS : 75.84 (+15.03%)
RGC : 19.81 (+4.70%)
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL)....

REPL : 9.88 (+1.96%)
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their...

REPL : 9.88 (+1.96%)
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm

NEW YORK , Sept. 22, 2025 /PRNewswire/ --

REPL : 9.88 (+1.96%)

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 10.58
2nd Resistance Point 10.36
1st Resistance Point 10.12
Last Price 9.88
1st Support Level 9.66
2nd Support Level 9.44
3rd Support Level 9.20

See More

52-Week High 14.80
Fibonacci 61.8% 10.17
Last Price 9.88
Fibonacci 50% 8.74
Fibonacci 38.2% 7.31
52-Week Low 2.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar